Neurol. praxi. 2011;12(1):43-47

Contemporary treatment options for Lennox-Gastaut syndrome

MUDr.Michal Ryzí
Klinika dětské neurologie LF MU a FN Brno, Centrum pro epilepsie Brno

The Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies of childhood onset. LGS is characterised by

occurence of multiple type of epileptic seizures (tonic, atonic, atypical absences), an EEG finding, psychomotor delay and behaviour

disorders. The optimum treatment for LGS remains uncertain. This paper summarizes the therapeutical options of LGS including pharmacological

therapy, diet and surgery. No study has shown any one drug to be highly efficacious; rufinamide, lamotrigine, topiramate

and felbamate may be helpful as add-on therapy. Until further research has been undertaken, clinicians will need to continue to consider

each patient individually, taking into account the potential benefit of each therapy weighed against the risk of adverse effects.

Keywords: Lennox-Gastaut syndrome, pharmacological treatment, ketogenic diet, VNS

Published: February 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryzí M. Contemporary treatment options for Lennox-Gastaut syndrome. Neurol. praxi. 2011;12(1):43-47.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bergqvist Ch, Schall J, Gallagher P, Cnaan A, Stallings V. Fasting versus Gradual Initiation of the Ketogenic Diet: A Prospective, Randomized Clinical Trial of Efficacy. Epilepsia, 2005; 46(11): 1810-1819. Go to original source... Go to PubMed...
    2. Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet Ch, et al. Epileptic syndromes in infancy, childhood and adolescence. 3rd ed. London: John Libbey Ltd, 2002: 113-135.
    3. Ferlazzoa E, Nikaronova M, Italiano D, Burelu M, Dravec CH, Calarese T, Viallat D, Kölmet M, Bramanti P, De Santi L, Genton P. Lennox-Gastaut syndrome in adulthood: Clinical and EEG features Epilepsy research, 2010; 89(2): 271-277. Go to original source... Go to PubMed...
    4. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double blind trial. Neurology 370 2005; 64(Suppl. 1): 1826. Go to original source...
    5. Heiskala H. Community-based study of Lennox-Gastaut syndrome. Epilepsia. 1997; 38(5): 526-531. Go to original source... Go to PubMed...
    6. Kolníkova M, Sýkora P. Ketogénna diéta - alternatívna liečba farmakorezistentnej epilepsie. Neurol pre prax 2005; 3: 154-156.
    7. Komárek V. Léčba epileptických syndromů u dětí. Cesk. Slov. neurol. 2007; 70/103(5): 473-487.
    8. Kuba R. Antiepileptika a jejich klinické použití v epileptologii. Prakt. lékáren. 2010; 6(2): 62-66.
    9. Lassonde M, Sauerwein C. Neuropsychological outcome of corpus callosotomy in children and adolescents. J Neurosurg Sci. 1997; 41(1): 67-73. Go to PubMed...
    10. Lee Y, Kang H, Lee J, Kim S. Resective pediatric epilepsy surgery in Lennox-Gastaut syndrome Pediatrics, 2010 - Am Acad Pediatrics. Go to original source...
    11. Matsuo F. Lamotrigine. Epilepsia Volume 40, pages, 1999: 30-36. Go to original source... Go to PubMed...
    12. Motte J, Trevathan E, Arvidsson JFV, Barrera M, Mullens E, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337: 1807-1812. Go to original source... Go to PubMed...
    13. Ošlejšková H. Zhoršování epileptických záchvatů a epilepsií antiepileptiky - Cesk Slov Neurol N. 2007; 70/103(2): 137-142.
    14. Pellock J, Faught E, Leppik I, Shinnar S, Zupanc M. Felbamate: Consensus of current clinical experience. Epilepsy Research 2006; 71: 89-101. Go to original source... Go to PubMed...
    15. Pellock J, Dodson W, Bourgeois B. Pediatric epilepsy: diagnosis and therapy - Medical 2008: 895.
    16. Ritter FJ. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29-33. Go to original source... Go to PubMed...
    17. Sachdeo R, Glauber T, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox- Gastaut syndrome Neurology 1999; 1(52): 1882. Go to original source... Go to PubMed...
    18. Sýkora P. Liečba epileptických syndrómov v detskom veku s nepriaznivou prognózou Neurol. pro praxi 2007; 2: 91-93.
    19. Velasco A, Velasco F, Jiménez F, Velasco M, Castro G, Carrillo-Ruiz JD, Fanghändel G. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia 2006; 47: 1203-1212. Go to original source... Go to PubMed...
    20. Wheless J, Clarke D, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007; 9: 353-412. Go to PubMed...
    21. Wheless J, Clarke D, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005; 20: S1-56. Go to original source... Go to PubMed...
    22. You S, Kang H, Kim H, Lee H, Ko T. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev. 2008; 30(4): 287-290. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.